Plavix has a unique mechanism of action by blocking the amplification of platelet activation by released ADP, and often used with aspirin to prevent the risk of clots for the first year after DES implant.
Plavix and aspirin have different mechanism of action to prevent clots. After a year,
plavix is usually discontinue as the risk for clots is decreased, and aspirin is continued long term. The risk of a clot is about 3%.